8
Participants
Start Date
February 2, 2022
Primary Completion Date
July 25, 2023
Study Completion Date
July 25, 2023
BIIB132
Administered as specified in the treatment arm
BIIB132-Matching Placebo
Administered as specified in the treatment arm
Columbia Univeristy Medical Center, New York
Pennsylvania Neurological Institute, Philadelphia
University of Florida, Center for Movement Disorders, Gainesville
Movement Disorder Center Florida, Tampa
Universitaetsklinikum Essen Klinik für Neurologie, Essen
Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE), Bonn
Washington University, St Louis
UniversitaetsklinikumTübingen Neurologische Universitätsklinik, Tübingen
Houston Methodist Research Institute, Houston
University of California - Los Angeles, Los Angeles
University of California San Francisco, San Francisco
University of Washington, Seattle
Tel Aviv Sourasky Medical Center, Tel Aviv
Massachusetts General Hospital, Boston
Universitair Medisch Centrum Groningen (UMCG), Groningen
Radboudumc, Nijmegen
Centro Hospitalar de Lisboa Norte, Lisbon
Centro Hospitalar do Porto, Porto
University College London Hospital (UCLH), London
Churchill Hospital, Oxford
Lead Sponsor
Biogen
INDUSTRY